Last reviewed · How we verify
TFV IVR
At a glance
| Generic name | TFV IVR |
|---|---|
| Also known as | Tenofovir Intravaginal Ring |
| Sponsor | CONRAD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir (PHASE1)
- Tenofovir/Levonorgestrel Intravaginal Ring and Tenofovir Intravaginal Ring (PHASE2)
- Safety, PK, and PD Study of IVRs Releasing TFV and LNG (PHASE1)
- Exploratory Pharmacodynamic Study of Tenofovir-Based Products (PHASE1)
- Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone (PHASE1)
- In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TFV IVR CI brief — competitive landscape report
- TFV IVR updates RSS · CI watch RSS
- CONRAD portfolio CI